Eli Lilly is spending $3.25 billion to acquire Kelonia Therapeutics, a small biotech company developing cell therapies for cancer and autoimmune diseases, the companies announced Monday.
Lilly could pay more if Kelonia achieves specified clinical, regulatory, and commercial milestones.
The acquisition is a boon for the small startup, which has subsisted on $60 million over the last five years and previously struggled to stay afloat. Three times, the company came within a week of running out of cash, according to Bryan Roberts, a partner at the venture capital firm Venrock, which incubated the biotech.
Following the announcement of Lilly’s acquisition, Roberts shared these anecdotes along with the original investment memo and slide deck once used to get Kelonia — then called Elcano Therapeutics — off the ground. The documents offer a rare look at the process of starting a biotech company, including how investors assessed the “kajillion gene therapy efforts” to contend with.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
